Skip to content

A study of exercise versus rest in myasthenia gravis

Efficacy and safety of exercise in mild to moderate myasthenia gravis: an open labeled controlled trial. - RESTOREX MG

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/11/021869
Enrollment
40
Registered
2019-11-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G700- Myasthenia gravis

Interventions

Intervention1: Exercise: Exercise arm: 2-3 supervised walking sessions of 30 min., starting with 10 min. walking the first week, 20 min. in second week and 30 min. in third week. After 4, 8 and 12 wee

Sponsors

Prinicipal Investigator
Lead Sponsor
World Congress of Neurology
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. MG patients attending the neurology Outdoor or indoor services of SGPGIMS. 2. MGFA score of stage II to III. 3. Able to undergo 6minute walk test

Exclusion criteria

Exclusion criteria: 1. Enrolled in another trial. 2. Contraindications to exercise like coronary artery disease and stroke and pulmonary disease, osteoarthritis, pregnancy or medical condition reducing survival to less than 2 years. 3. Hospitalization in past 8 weeks. 4. MGFA score of stage I, IV or V. 5. MGQOL score > 45.

Design outcomes

Primary

MeasureTime frame
MGQOL-15 scoreTimepoint: 1,2 and 3 months

Secondary

MeasureTime frame
1. Increase in the dose of AchEIs drugs or additional immunosuppression or use of PE,IVIG. 2. Myasthenic muscle score: at 1,2 and 3 month. 3. Change in MGADL. 4. Grip strength. 5. Six min walk test. 6. RNS in Trapezius 7. Micro RNA: -150 -5P and micro RNA- 21- 5P. 8. Endorphin and its receptors.Timepoint: 1,2 and 3 months

Countries

India

Contacts

Public ContactDr Usha Kant Misra

SGPGIMS Lucknow

drukmisra@rediffmail.com05222494167

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 16, 2026